Early contributors to the success of anti-COVID vaccines
The paper of Gregory Gregoriadis brings into sharp relief the contrast in time taken for ‘individual technologies to emerge from research, find market opportunities and make a tangible impact’ [1]. This short commentary highlights some early events that were to underpin the success of a new anti-COV...
Main Author: | Brian Heap |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Medicine in Drug Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590098621000269 |
Similar Items
-
Liposomes and mRNA: Two technologies together create a COVID-19 vaccine
by: Gregory Gregoriadis
Published: (2021-12-01) -
Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines
by: Thai Thanh Hoang Thi, et al.
Published: (2021-04-01) -
Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review
by: Ehsan Raoufi, et al.
Published: (2021-05-01) -
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism
by: S Amanpour
Published: (2021-03-01) -
Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System
by: Roozbeh Nayerhoda, et al.
Published: (2019-09-01)